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Inhibitor Specificity via Protein Dynamics:
Insights from the Design of Antibacterial Agents
Targeted Against Thymidylate Synthase
[2–4]. Hydrophobic regions, complementary to drug
molecules, which tend to be more hydrophobic than
natural protein ligands, can become exposed to the li-
gand upon binding [5]. The change in conformation of
a protein upon ligand binding can be considered as
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41100 Modena induced fit or as the selection, from a range of preex-
isting protein conformations around the native state, ofItaly
2 European Molecular Biology Laboratory a conformation that is complementary to the incoming
ligand [6]. An excellent example of these phenomenaMeyerhofstr 1
D-69112 Heidelberg can be found in antibody binding kinetics, recently in-
vestigated by James and coworkers [7]. The necessity3EML gGBMH
Villa Bosch, Schloss-Wolfsbrunnenweg 33 of treating proteins not as single experimentally deter-
mined structures but as dynamic entities in equilibriumD-69118 Heidelberg
Germany among different conformational states therefore arises
[8–10]. Then, if each conformational state can be con-
sidered to have a different affinity for the ligand, the
experimentally measured affinity is given by a suitablySummary
weighted average of the binding energy to different con-
formations. Binding to a given protein conformation de-Structure-based drug design of species-specific in-
pends not only on the conformation’s binding energyhibitors generally exploits structural differences in
but also on its accessibility to the ligand. Protein motionsproteins from different organisms. Here, we demon-
can result in conformational gating, which can affect thestrate how achieving specificity can be aided by tar-
specificity and kinetics of binding [11, 12]. In acetylcho-geting differences in the dynamics of proteins. Thymi-
linesterase, for example, conformational gating modu-dylate synthase (TS) is a good target for anticancer
lates access of the substrate to the active site and isagents and a potential target for antibacterial agents.
important for enzyme specificity and efficiency [11].Most inhibitors are folate-analogs that bind at the fo-
Conformational gating may provide geometric selectiv-late binding site and are not species specific. In con-
ity, e.g., by preventing binding of larger ligands andtrast, 156 is not a folate-analog and is specific for
permitting binding of smaller ligands. Conformationalbacterial TS; it has been shown crystallographically to
gating also affects the rate of ligand binding and doesbind in a nonconserved binding site. Docking calcula-
so in a manner that depends on the relative timescalestions and crystal structure-based estimation of the
of the protein gating motions and the process of ligandessential dynamics of TSs from five different species
binding [13].show that differences in the dynamics of TSs make
Treating protein dynamics is a challenge in the com-the active site more accessible to 156 in the prokary-
parative analysis of isozymes. Often, isozymes haveotic than in the eukaryotic TSs and thereby enhance
high sequence homology and a highly conserved struc-the specificity of 156.
tural fold, especially in the catalytic domain. But they can
have different molecular properties, including different
Introduction dynamics that affect binding and catalysis. To date,
most structure-based drug design studies aimed at de-
The structure-based drug design paradigm is applicable signing species-specific ligands have made use of dif-
to the discovery of new molecules that inhibit the biologi- ferential interaction models that consider solely the
cal functions of selected macromolecular targets, structure/sequence differences among isozymes [14,
whose 3D structures are known. The technique has been 15]. However, the shortcoming of this approach was
successful, resulting in clinically useful drugs [1]. How- highlighted recently by the observation of Agard et al.
ever, there are several bottlenecks to its wider applica- [16] that differences in protein dynamics between the
tion. One of these is the treatment of the flexibility of wild-type and a single point mutant of -lytic protease
the receptor macromolecule. Exploration of the confor- could explain the different spectrum of ligands hy-
mational space of a macromolecule in drug design is drolyzed by these enzymes.
often limited to those conformations whose 3D struc- In the present paper, we examine the molecular basis
tures have been determined experimentally, and confor- of species-specific thymidylate synthase (TS) inhibition
mational changes occurring upon ligand binding are fre- by phenolnaphthalein derivatives. TS is an essential
quently partially or fully neglected. enzyme with a fundamental role in DNA synthesis. TS
The experimentally determined conformation of a pro- catalyzes the methylation of 2-deoxyuridine-5-mono-
tein often differs in its ligand-bound and -unbound phosphate (dUMP) to form 2-deoxythymidine-5-mono-
forms. Protein conformational changes can open new phosphate (dTMP), with a molecule of N5,N10-methylene-
ligand binding sites that are difficult to predict a priori tetrahydrofolate (mTHF) as a cofactor. Crystal structures
solved in the presence of reaction intermediate analogs
show that structural changes that occur throughout the*Correspondence: ferrari.stefania@unimore.it
Chemistry & Biology
1184
protein are integral to the enzymatic reaction mecha- dynamics of TSs from different species could affect
nism [17]. 156 binding and consequently provide an explanation
dUMP methylation is the final step in the sole de novo for its species specificity.
biosynthetic pathway of dTMP. The blockage of this
process leads to cell death. TS is present in almost
all living organisms, is very conserved among different Results and Discussion
species, and is highly specific in its catalytic function
[18]. TS inhibitors can interfere with either the dUMP- Inhibition Activity Profiles
enzyme or the mTHF-enzyme interaction. Because of Enzymatic inhibition assays against TS from two bacte-
its essential role in cell replication, TS has been consid- rial species (LcTS, EcTS) and three nonbacterial species
ered a good target for anticancer therapy [4]. It is only (hTS, PcTS, and LmTS) were carried out for six phenol-
recently that researchers have started to study TS as naphthalein derivatives as well as for the folate-analog
an antibacterial drug target [19]. To use TS inhibitors in CB3717 (see Experimental Procedures). The inhibition
antibacterial therapy, the inhibitors should have spe- activity profiles reported in Table 1 show that all the
cies-specific activity profiles, i.e., they should inhibit phenolnaphthalein derivatives have species-specific
bacterial TS without affecting human TS (hTS). activity toward bacterial species, whereas they show
Recently, Stout et al. [19] discovered a new phenol- much weaker or undetectable inhibition against eukary-
naphthalein compound (156) that inhibits Lactobacillus otic species (human, Pc, and Lm). The specificity index
casei TS (LcTS) with a Ki value 43 times lower than that between LcTS and hTS varies from 20 to over 306 for
against hTS (Ki  0.7 and 30 M, respectively) (Table 1). the most specific compound (2). For PcTS, the specific-
The determination of the crystal structure of the binary ity index ranges from 12 to over 251 (1), and for LmTS
LcTS-156 complex [19] revealed that this compound it ranges from 10 to over 1546 (156).
binds in a nonconserved region of the enzyme active In contrast, the folate-analog CB3717 shows a non-
site more than 5 A˚ from the binding site of folate-analog species-specific inhibition activity profile, inhibiting the
compounds. It interacts with the “small domain” (SD) TSs of all species tested at approximately the same
(Figure 1), which consists of a sequence of 70 residues level (Ki  0.03–0.24 M).
in LcTS, but is reduced to 32 residues in hTS [20]. The The species-specific activity profile of these phenol-
first hypothesis formulated to explain 156 activity data naphtalein compounds can be understood through the
relied on the structural difference in the SD region be- analysis of their binding site in TS enzymes.
tween LcTS and hTS. That is, it was proposed that 156
is species specific because it binds in a species-specific
site of the enzyme where it exploits structural differ- Binding Sites of Inhibitors
ences in the SD between hTS and LcTS. Further investi- The crystal structures of the LcTS-156 [19] and LcTS-
gation of the inhibition activity data profile of 156 [21] dUMP-CB3717 [22] complexes show that 156 binds in
surprisingly revealed that this compound shows the a poorly conserved site that is distinct from the substrate
same affinity toward TSs from Escherichia coli (EcTS) (folate) binding site in which CB3717 binds (Figure 1).
(Ki  0.6 M) as from Lc even though the SD region of The interaction with less conserved subsites of the en-
EcTS is reduced to only 20 residues. This observation zyme, such as the SD region, allows 156 to exploit the
prompted these questions: how can 156 discriminate differences between TSs from different species.
among different TSs and which relations exist between Crystal structure analysis of hTS, LcTS, EcTS, PcTS,
its binding mode and its inhibition activity profile? To and LmTS [19, 22, 26–32] (see Table S1 in the Supple-
address these issues, we deemed it necessary to con-
mental Data available online at http://www.chembiol.
sider not only static structural differences between TSs
com/cgi/content/full/10/12/1183/DC1) reveals the greater
of different species but also how structural differences
similarity of the ternary folds of hTS, PcTS, and LmTS to
can influence protein dynamics and flexibility and how
each other than to the bacterial TSs (LcTS and EcTS).these enzyme features can affect ligand binding, and in
These two groups are distinguished most prominentlyparticular the 156 binding site conformation.
in the SD and the dimer interface loop (HIL) (Figure 1).In this paper, we report on the evaluation, by experi-
On the other hand, it might be expected that the 156ment and computation, of the inhibition activity profile
binding sites in LcTS and EcTS share common featuresof 156 and five other phenolnaphthalein derivatives,
that result in their similar Ki values for the phenolnaph-as well as the nonspecific folate-analog inhibitor CB3717
thalein derivatives. However, the large SD that is present[22], toward five different TS isozymes (LcTS, EcTS, hTS,
in LcTS compared to the smaller SD in eukaryotic TSsPneumocystis carinii TS [PcTS], and Leishmania major
is apparently not the only critical factor for binding, sinceTS [LmTS]). The inhibitor binding sites, the protein con-
EcTS lacks the majority of the SD. The variation in theformational changes upon ligand binding, and the struc-
SD suggests that, beyond structural and sequence fea-tural differences among TSs from different species were
tures of TS in different species, there should be anotherstudied by crystal structure comparison and molecular
key feature that differentiates eukaryotic TSs from bac-docking. Because differences in sequence and struc-
terial TSs and is exploited by phenolnaphthalein com-ture, as deduced from crystal structure comparison
pounds in their interaction with the enzyme.alone, were not sufficient to explain the specific activity
An important aspect to consider is the changes inof156, we analyzed the structural flexibility of TSs from
the enzyme conformation induced by ligand binding.different species using CONCOORD-essential dynamics
[23, 24] analysis, focusing on how differences in the Comparison of the LcTS-156 binary complex and the
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Table 1. Inhibition Activity Profile of Six Selective Phenolnaphthalein Derivatives and of the Nonselective Folate-Analog CB3717 against
TS Enzymes from Five Different Species
Ki (M)
LcTS EcTS hTS PcTS LmTS
156 0.7a 0.6b 30a 13 1082c
1 1.6a 1.1 402c 402c 1775c
2 0.8 4.1 245c 28 1082c
3 1.8 1.1 245c 22 1082c
4 6.6 0.9 132c 132c 63d
5 1.7 8.5 245c 32.7d 41d
CB3717 0.06 0.06 0.03 0.24 0.08
a [25].
b [21].
c Calculated assuming 2% inhibition at the maximum solubility concentration (27 M for compound 4; 50 M for compounds 156, 2, 3, and
5; and 82 M for compound 1).
d Calculated from the inhibition percentage measured at the maximum solubility concentration (16% and 35%, respectively, for compounds
4 and 5, versus LmTS; 13% for compound 5 versus PcTS).
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Figure 1. LcTS Structure and Inhibitors’ Binding Sites
LcTS dimer with one monomer in gray and the other in light blue ([A] and [B], coordinates from PDB files 1TSL); in the first monomer, important
regions (loop around H25 [H25], small domain [SD], dimer interface loop [HIL], catalytic loop [CL], and C terminus [CT]) are colored in orange.
In (B), the enzyme is rotated about the vertical axis by ca. 90 compared with its orientation in (A). The Connolly surface of LcTS (C) is shown
with CB3717 (folate-analog, cyan; PDB identifer, 1LCA) and 156 (cyan; PDB identifier, 1TSL) binding sites. The active site surface (orange,
10 A˚ around the dUMP binding site), the folate and folate-analog binding site (red, 4 A˚ around folate binding site), and the 156 binding site
(yellow, 4 A˚ around 156 binding site) are shown. The SD region has been removed to make the complete active site visible. The enzyme
orientation is the same as in (B).
apo-enzyme structures [19, 22, 26] reveals that 156 cause the 156 binding site is not accessible, we con-
sider the noncovalent ternary complex of LcTS [22] todoes not induce significant conformational changes in
the enzyme upon binding (the structures can be super- be a closed form of TS, even though the closed confor-
mation of TS is usually defined as the covalent ternaryimposed with a C rmsd of 0.35 A˚). In contrast, when
the ternary complex with dUMP and a folate-analog complex of TS in the literature [2]. The 156 crystallo-
graphic binding site is also not accessible in the struc-inhibitor is formed, the enzyme undergoes major confor-
mational changes [22, 28, 29]. These involve the C termi- tures of the hTS ternary complex deposited in the Pro-
tein Data Bank [33] until now. This is due to R50 andnus (CT), the loop around H25 (H25), and the SD (Figure
1) [22]. This suggests that these flexible regions can T51 moving toward V311 and F117 and other residues
(A111, N112, S120, and L121) restricting the binding sitemove most easily to accommodate the binding of differ-
ent ligands. These regions constitute the binding site of of 156. This is true also for the structure 1I00 [30], a
noncovalent ternary structure of hTS. Comparison of156 (Figure 1), and therefore, this site could be affected
by conformational changes of the enzyme. the ternary complex structures, with dUMP and a folate-
analog inhibitor (such as CB3717 or ZD1694), of the TSComparison of the LcTS-156 binary complex with
the LcTS-CB3717-dUMP ternary complex [19, 22] enzymes from different species (Lc, Ec, Pc, Lm, and
human [22, 28, 29, 31, 32]) shows that the conformationshows that the conformations of R23, H106, and V316
affect the binding of 156. In the ternary noncovalent adopted by the enzyme is mostly conserved. However,
the degree of closure could be different for the differentcomplex, all these residues are rotated so that the crys-
tallographic binding site of 156 is not accessible. Be- species and could be the key to differentiating eukary-
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Figure 2. Autodock-Bound Conformations
The bound conformations obtained with Au-
todock (blue) are shown for LcTS (A), EcTS
(B), and hTS (C). The protein surface is shown
with the active site (orange), the folate (red),
and the 156 (yellow) binding sites, as in (C),
from the same viewpoint. In (A), the SD region
has been removed to make the complete ac-
tive site visible.
otic TSs from bacterial TSs and explaining the basis of late binding site is not in contrast with the crystallo-
graphic conformation seen in LcTS-156 complex. Inthe species-specific activity of 156 and phenolnaph-
thalein derivatives. fact, site-directed mutagenesis and enzyme kinetic ex-
periments [19] have previously pointed to a multiple
binding mode for 156 to TS.Molecular Docking
The docking program, AutoDock 3.0.5 [34], was used For each calculated binding site, multiple orientations
were predicted for 156. These multiple orientationsto identify favorable binding sites for 156 in TSs from
bacterial and eukaryotic species. To explore the whole result from the pseudo-3-fold symmetry of the 156
molecule. In Figures 2A, 2B, and 2C, the range of boundbinding site of TS, docking was performed for open
protein conformations only (see Experimental Proce- conformations obtained by AutoDock in Lc, Ec, and
human TS are shown. Two of the binding modes com-dures).
For the four isozymes, LmTS, hTS, LcTS, and EcTS, puted for 156 in LcTS are compared with the crystallo-
graphic binding sites of CB3717 and 156 in Figures 3AAutoDock predicts different possible binding modes ei-
ther in the folate binding site or in the 156 crystallo- and 3B [19, 22].
In the folate binding site (Figure 3A), 156 forms threegraphic binding site (Figure 2). The folate binding site
is computed to be energetically more favorable than the hydrogen bonds, through its two hydroxyl groups and
its carbonyl group, with D221, E60, and W85. D221 andlatter binding site (by about 1–1.7 kcal/mol in Lc, Ec,
and human TS and about 3 kcal/mol in LmTS) (Table 2). E60 are conserved among all the species, whereas W85
is conserved between Lc and Ec TSs but is replaced byThe identification of docked conformations at the fo-
Table 2. Results of Docking Compound 156 to LcTS, EcTS, LmTS, and hTS using AutoDock 3.0.5
Folate 156
%LCPa Gbindb Gbindc %LCPa Gbindb Gbindc
HTS 30 	8.47 	7.77 52 	7.41 	5.65
LmTS 36 	10.62 	7.12 46 	7.60 	7.49
LcTS 38 	8.41 	8.08 30 	7.06 	7.01
EcTS 34 	9.48 	7.57 30 	7.75 	7.27
a Percentage of ligand docking positions predicted at the specified site (folate or 156).
b Estimated free energy of binding (kcal/mol) of the best-scored ligand conformation at the specified site.
c Average estimated free energy of binding for docked ligand configurations in the whole binding site (see Experimental Procedures).
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ture, the interaction with D103 is mediated through a
well-ordered water molecule, and the carbonyl group of
156 interacts with a second well-ordered water mole-
cule [19]. These water molecules were not considered
during the calculation, and this fact provides an explana-
tion for the slight differences between the crystallo-
graphic binding mode and the predicted one. Unlike the
folate binding site, this binding site is highly species
specific. In particular, LcTS residues D103, F104, G105,
and H106 are in the SD and are absent in other species.
E84 is substituted by an alanine in Lm and hTS and a
glycine in PcTS. W85 (which also contributes to the
folate binding site, see above) is replaced by an aspara-
gine in Lm, Pc, and hTS. E88 is substituted by an arginine
in Lm, Pc, and hTS, and it is conserved in EcTS but has
a different orientation because of the big differences in
the nearby SD region. Other residues are conserved but
are part of highly flexible regions, such as the catalytic
loop (CL), CT, and H25.
Despite the differences in the 156 crystallographic
binding site among Lc, Ec, Lm, and hTS, AutoDock pre-
dicts binding positions for the ligand in this site in all the
enzymes, although with slightly different binding modes.
The docking procedure correctly reproduced experi-
mentally observed multiple binding modes for156. This
supports its use in further calculations to locate potential
ligand binding sites. On the other hand, the AutoDock-
estimated free energies of binding of the ligand to the
two identified sites indicate that the crystallographic
binding site of 156 is energetically less favorable than
the folate binding site in all isozymes. This shows that
the dominant conformation––as observed in the crystal
structure with LcTS––cannot be easily detected from
the ensemble of possible conformations resulting from
the docking to the protein conformation in this crystalFigure 3. 156 Autodock-Bound Conformations Overlaid on
CB1717 and 156 Crystallographic-Bound Conformations structure. This docking study nevertheless suggests
Two LcTS-bound conformations (yellow) obtained with Autodock that the inhibition activity of 156 toward TS is the result
are overlaid on bound conformations from crystal structures (cyan) of the binding of the ligand in two possible sites in
of CB3717 ([A], 1LCA) and 156 ([B], 1TSL). In (A) matched to W85 multiple orientations.
there is the corresponding asparagine residue from hTS (orange,
coordinates from PDB files 1HVY).
Protein Flexibility
As the binding pattern of 156 toward the four enzymesan asparagine in Pc, Lm, and human TSs. However, an
asparagine in this position is probably able to form a (LcTS, EcTS, LmTS, and hTS) predicted by AutoDock
does not explain its species-specific inhibition profile,hydrogen bond with the carbonyl group of the ligand so
that this intermolecular interaction would be conserved the structural flexibility of TSs from five different species
was investigated. Computational techniques were ap-(Figure 3A). The ligand also forms van der Waals interac-
tions with dUMP, H80, I81, W82, G225, and F228. All of plied to explore the conformational space and identify
principal components of motion of these protein struc-these residues except for H80 are conserved among the
five TSs. H80 is substituted by lysine in hTS, LmTS, and tures.
First, the CONCOORD [24] method was used to gener-PcTS and threonine in EcTS. Since H80 interacts through
its main chain with the ligand, the variation of this residue ate an ensemble of structures representing the available
conformational space of the protein as determined fromdoes not affect the possibility for the residue to interact
with the ligand. In conclusion, the folate binding site is the crystal structure. The structures are generated by
a random search for structures that satisfy distancehighly conserved in all the species, and it is anticipated
that 156 can most probably bind in the folate binding constraints derived from analysis of the geometry and
strengths of interatomic interactions in the crystal struc-site in all the species.
In the binding mode predicted by AutoDock for 156 ture. The CONCOORD ensemble of structures (Catoms
only) was then subjected to an essential dynamics [23,in its crystallographic binding site in LcTS (Figure 3B),
the ligand makes two hydrogen bonds through its hy- 35] analysis to identify the principal components (or
eigenvectors) of motion described by the CONCOORDdroxyl groups with D103 and E84. The ligand also makes
van der Waals interactions with T24, W85, E88, F104, ensemble. These eigenvectors are ranked by decreasing
eigenvalues. The eigenvalues quantify the contributionG105, H106, A194, V316, and R179. In the crystal struc-
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Figure 4. Proportion of the Overall Motion
Described by the First Six Eigenvectors Iden-
tified by Essential Dynamics
Analysis of the CONCOORD structural en-
semble for TSs from five organisms.
of the eigenvectors to describing the whole CONCOORD blue and the other in red, were superimposed in order
to highlight how the different regions of the156 bindingensemble. Typically, a small number of eigenvectors
account for most of the variation in conformation in site move.
The fourth through sixth eigenvectors are less impor-the CONCOORD ensemble. The CONCOORD essential
dynamics analysis highlights differences in the flexibility tant in describing the conformational space of the pro-
teins (
8%). In all enzymes, they correspond to 156of TSs in different species that aid explanation of the
species-specific inhibition activity of 156. In particular, binding site closing/deforming motions. Thus, LcTS and
EcTS also have 156 binding site closing (and re-clear differences emerge between bacterial (Lc and Ec)
and eukaryotic (human, Lm, and Pc) TSs. opening) motions, but these are modest compared to
those in the eukaryotic TSs.
Summarizing, in hTS, LmTS, and PcTS, closure/defor-CONCOORD Essential Dynamics Analysis
mation of the 156 binding site is one of the principalThe first eigenvector detected in the essential dynamics
components of the flexibility of these structures as high-analysis plays the major role in describing the overall
lighted in the second and the third eigenvectors; in LcTSconformational space explored by the enzyme (account-
and EcTS, this motion is a minor component of theing for 29%–41% of the overall motion, Figure 4). The
flexibility of the protein structures that is apparent only inmotion along this eigenvector does not affect the bind-
eigenvectors with lower eigenvalues. As a consequence,ing site of 156. Despite the structural differences
the 156 binding site is more accessible in the LcTSamong TS species in the SD region, this eigenvector is
and EcTS structures than in the hTS, LmTS, and PcTSalmost the same in all the enzymes. The only region
structures.significantly different is the HIL region. This loop is
AutoDock calculations were performed for represen-shorter in LcTS and EcTS than in the other enzymes
tative conformations of Lc, Ec, and human TSs extractedconsidered, and it is turned toward the intermonomer
from the CONCOORD ensembles (see Experimental Pro-interface where it moves together with the whole inter-
cedures) in order to obtain an estimate of how muchface region. In hTS, LmTS, and PcTS, this loop is longer
the enzyme flexibility affects the docking of 156. Theand turned toward the SD region. As a consequence,
results show that 156 binds to 100% of the representa-in the latter enzymes, the HIL and SD regions show the
tive conformations of LcTS and EcTS but only a subsetsame motion along the first eigenvector.
of the representative conformations in hTS, correspond-The second and third eigenvectors together describe
ing to 64% of the whole CONCOORD ensemble of 50020%–26% of the whole conformational space explored
structures. In the remaining 36% of conformations of(Figure 4). Both these vectors show a different type of
hTS, the ligand cannot reach the active site and bindsmotion in LcTS and EcTS compared with hTS, LmTS,
at the surface of the enzyme.and PcTS. In LcTS and EcTS, both vectors show that the
The closed conformations from the CONCOORD en-SD, the H25, the CT, and the CL regions move together in
semble in hTS resemble the crystal structure as far asthe same direction. The motion along these vectors does
the type of shifts at the SD, CT, and H25 regions arenot affect the accessibility of the 156 binding site. On
concerned but do not reproduce the changes in confor-the other hand, in hTS, PcTS, and LmTS, motion along
mation of these regions themselves that are seen in thethese vectors results in closing (and subsequent re-
experimental structure. The representative structuresopening) of the 156 binding site because the top (SD
from the CONCOORD ensemble for LcTS all permit ac-and CL) and the bottom (H25 and CT) of the site move
cess of 156. Thus, the main conformations sampled intoward each other. Figure 5 shows the second eigenvec-
the CONCOORD ensemble do not close to the extenttor for LcTS (Figure 5A) and hTS (Figure 5B). For each
enzyme, two conformations along the motion, one in of the crystal structure of LcTS.
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cific enzyme inhibition can be achieved by exploiting
not only static structural differences in protein struc-
ture but also differences in protein dynamics and flexi-
bility across species. We studied a set of inhibitors of
TS, a highly conserved enzyme that is a potential target
for antibacterial agents. We measured inhibition con-
stants for six phenolnaphthalein analogs. In contrast
to nonspecific folate-analog inhibitors, all these com-
pounds showed species specificity, inhibiting bacte-
rial species better than eukaryotic species. We used
computational techniques to explore the basis for the
species specificity of the phenolnaphthalein analogs.
In molecular docking calculations, it was possible for
the phenolnaphthalein derivatives to bind at both the
classical folate binding site and a second more spe-
cific binding site in all the TS proteins studied. How-
ever, our analysis of protein flexibility shows that bind-
ing site closing motions in eukaryotic TSs appear to
make the 156 binding site less accessible than in the
bacterial TSs. Our results thus suggest that the TS
species specificity of phenolnaphthalein derivatives
results not only from differences in structure but also
from differences in protein dynamics. The insights ob-
tained from the present study show how protein dy-
namics can influence ligand specificity and point to
the importance of exploiting species-dependent varia-
tions in protein dynamics in the structure-based de-
sign of specific compounds.
Experimental Procedures
Experimental Inhibition Activity Profile Evaluation
All reactants used for enzyme purification and inhibition assays were
at the maximum commercially available purity grade. 6R-N5,N10-
methylen-5,6,7,8-tetrahydrofolate was kindly provided by EPROVA
(Schaffhausen, Switzerland). CB3717 was a gift of R.M. Stroud
(UCSF).
Chemistry
Compounds 156 (referred to as 5c in [25] and as 4 in [19]) and 1–5
were synthesized at the University of Modena and Reggio Emilia
(M.P. Costi) and at the University of Milano (D. Barlocco). Their purity
grade was the maximum obtainable. Synthesis of these compounds
will be described elsewhere (our unpublished data).
Enzyme Purification
All the strains and the plasmids were provided by D.V. Santi at the
University of California, San Francisco.
Expression and purification of EcTS, LcTS, PcTS, and hTS was
done following known procedures [21, 35–39]. The LmTS (pE1) plas-
mid [40] was expressed in Ec stain BL21(DE3)pLysS following the
procedure described by Hanan [41] and purified as reported in theFigure 5. Comparison of the Motion along the Second Eigenvector
literature [40]. The purified enzymes were stored at 	80C in 10 mMof the CONCOORD Ensembles
phosphate buffer (pH 7.0) and 0.1 mM EDTA (ethylene-diamine-Two conformations representing motion along the second eigenvec-
tetraacetic acid).tor are shown for LcTS (A) and hTS (B). For clarity, only the small
Enzyme activity was determined spectrophotometrically (Beck-domain (SD), catalytic loop (CL), C terminus (CT), and loop around
man DU640 spectrometer thermostated with HAAKE F3C) byH25 (H25) are shown in the second conformation (red). The double-
steady-state kinetic analysis, following the increasing absorbanceheaded arrows indicate the directions of motion, with the stars
at 340 nm due to the oxidation reaction of N5,N10-methylenetetrahy-showing the directions moved in simultaneously by different regions
drofolate to dihydrofolate [42]. Assays were performed at 20C inof the proteins.
the standard assay buffer formed by TES [N-tris(hydroxymethyl)
methyl-2-aminoethane-sulfonic acid] (50 mM) at pH 7.4, MgCl2 (25
mM), formaldehyde (6.5 mM), EDTA (1 mM), and 2-mercaptoethanol
(75 mM). Reaction solution (1 ml) was formed by standard assaySignificance
buffer (pH 7.4), dUMP (120 M), 6R-N5,N10-methylen-5,6,7,8-tetrahy-
drofolate (140 M), and enzyme (0.07 M).A crucial problem in the design of antimicrobial agents
Inhibition Assays
is to achieve sufficient specificity for proteins of the Stock solutions of the inhibitors were freshly prepared in DMSO
target organism so that side effects in humans are (dimethyl sulfoxide). The inhibition pattern for all of the compounds
was determined by steady-state kinetic analysis of the dependenceavoided. In this paper, we report on how species-spe-
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of the TS enzyme activity on folate concentration at varying inhibitor The 156 structure was taken from the crystal structure of the
LcTS-156 complex [19]. Atomic partial charges were assigned onconcentrations. The apparent inhibition constant (Ki) was obtained
by applying a suitable equation [43] for competitive inhibitors, intro- the basis of the Amber force field within the InsightII program [44];
for the atoms Cl1/Cl2 and C15/C21, (crystal structure numbering, Xn,ducing the appropriate experimental Km values (Michaelis-Menten
constant: 10 M for LcTS, 5 M for EcTS, 8 M for hTS, 16 M for from pdb files) charges of –0.15e and 0.15e, respectively, were as-
signed.PcTS, 94 M for LmTS). The specificity index of one compound
toward TS from one species (xTS) is obtained from the ratio between A cubic grid with sides 37.5 A˚ (for Lc, Ec, and Lm TSs) or 22.5 A˚
(for human TS) long, centered on the TS active site, was defined.its Ki(xTS) and Ki(LcTS). Each experiment was repeated at least three
times, and no individual measurement differed more than 20% from These grids are large enough to cover all the enzymatic active site.
A Lamarckian genetic algorithm was used to generate 50 boundthe mean.
conformations for 156 in each protein studied. All nonterminal
rotatable bonds were allowed to rotate during the calculation. AllComputational Studies
Structural Comparison of TS Enzymes from Different other settings were kept as default.
On the basis of the clustering histogram output from the AutoDockSpecies and Binding Site Analysis
Crystal Structure Analysis. Crystal structures of LcTS (4TSM, 2TDM, program [34], the lowest energy conformation of each cluster was
1THY, 1TSL, 1TSM, 1LCA) [19, 22, 26], EcTS (3TMS, 2TSC) [26, 28], selected. The selected conformations were grouped on the basis
and hTS (1HVY, 1HZW, 1I00) [29, 30] were taken from the PDB [33]. of their binding sites. Two main binding sites were considered, the
The crystal structures of the LcTS-phenolphtalein complex (TSPTH) folate and the 156 binding site. For each binding site, multiple
[27] and PcTS (PCTS) [32] were provided by R.M. Stroud (UCSF) and binding modes were considered. The average estimated free energy
that of LmTS (LMTS) [31] was provided by D.A. Matthews (Agouron of binding (Gbind, Table 2) for each binding site was calculated
Pharmaceuticals). When the asymmetric unit in the crystal was a as the simple mean of the estimate free energy of binding of each
monomer, the dimer was created with InsightII [44]. In some crystal conformation found in that binding site. All the conformations that
structures (4TSM, 1THY, 1LCA, 2TSC, LMTS), some residues on the were in other binding sites were not considered.
surface of the enzyme were lacking some atoms. Sequence errors, Protein Flexibility Analyses
such as a glutamic acid indicated as glutamine, were found in some Structures 1TSL, 1LCA, 3TMS, 2TSC, 1HVY, LMTS, and PCTS [19,
protein structures. For the structures considered only for visual 22, 26, 28, 29, 31, 32] were used in flexibility studies. All ligands and
analysis, the crystal structures were used “as is”; in all other cases, water molecules were removed. For 1LCA, 2TSC, and LMTS, the
the protein structures were corrected. The affected residues were corrected structures were considered.
corrected by adding missing atoms and, then, minimizing the resi- Essential Dynamics. The program CONCOORD [24] was first used
due conformation in the context of the enzyme structure with to generate an ensemble of 500 protein conformations. Then the
AMBER 6.0 [45]. Only corrected residues, ligands, water molecules, ESSDYN module of the program WHATIF [47] was used to analyze
and all hydrogen atoms of the system were allowed to move during the set of conformations and calculate its principal components.
the minimization. Parameterization of the protein-ligand complexes Essential dynamics analysis is based on calculation of the eigen-
was performed with the xLEaP module of AMBER 6.0 [45] using a vectors that are solutions of the atomic fluctuations covariance ma-
modified version of the parm94.dat force field. Atomic partial trix. Only C atoms were considered.
charges for dUMP were assigned on the basis of literature data Essential dynamics analysis was performed on LcTS, EcTS, LmTS,
[46]; atomic partial charges for the ligands were assigned using the PcTS, and hTS crystal structures. All parameters were kept at their
electrostatic potential charges (ESP) computed with the semiempiri- default values. Trials were done on LcTS and EcTS to verify that
cal MOPAC (MNDO) program interfaced to InsightII [44]. the conformational state of the starting structure (apo- or ternary
Molecular Docking. The program AutoDock 3.0.5 [34] was used complex structure) did not influence the results of calculation (data
for docking. The protein structure of LcTS was taken from the crystal not shown).
structure of the LcTS-156 complex 1TSL [19], after removal of the The CONCOORD ensembles of Lc, Ec, and human TS were ana-
ligand 156 and addition of a molecule of dUMP in place of the lyzed with NMRCLUST [48]. Forty-six, thirty-eight, and forty clusters
phosphate ion. The structure and coordinates of the dUMP molecule of different conformations were obtained for Lc, Ec, and human
were taken from the ternary complex structure of LcTS, 1LCA [22]. TSs, respectively. From the most populated clusters representative
For EcTS, the crystal structure of the unbound enzyme 3TMS [26] of 325, 370, and 375 out of 500 CONCOORD conformations, 13, 14,
was used. A molecule of dUMP, taken from the ternary complex and 17 conformations were selected for Lc, Ec, and human TSs,
structure of EcTS, 2TSC [28], was added in place of the phosphate respectively. These conformations were prepared and used in Auto-
ion. For LmTS, only the ternary complex crystal structure LMTS [31] Dock calculations as described above. The number of conforma-
was available. A first trial was done with this structure, but it was tions in each cluster was used to estimate the percentage of inhibitor
not possible to completely explore the binding site of 156 since binding for the whole ensemble.
the region of the enzyme corresponding to the crystallographic bind-
ing site of 156 in LcTS is not accessible in the ternary complex of
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